News

• 05 December 2025

  Jubilant Therapeutics Inc. appoints Daniel J. O’Connor as President and Chief Executive Officer

  Read More
• 25 October 2025

  Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor

  Read More
• 08 January 2024

  JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis

  Read More
• 15 June 2023

  Jubilant Therapeutics Inc. Appoints Nadir Patel as an Independent Member of Its Board of Directors

  Read More
• 13 April 2023

  Jubilant Therapeutics Inc.’s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models

  Read More
• 13 February 2023

  Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM)

  Read More
• 05 January 2023

  Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC)

  Read More
• 02 November 2022

  Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences

  Read More
• 07 September 2022

  The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils, Halts Cancer Progression and Metastasis

  Read More
• 03 August 2022

  Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

  Read More
• 01 June 2022

  Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  Read More
• 26 April 2022

  Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors

  Read More
• 11 April 2022

  Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

  Read More
• 10 March 2022

  Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022

  Read More
• 05 January 2022

  Jubilant Therapeutics Announces FDA Clearance of IND for JBI-802, a Novel Dual LSD1 and HDAC6 Inhibitor, for treatment of Solid Tumors

  Read More
• 10 November 2021

  Jubilant Therapeutics Inc to participate and present at upcoming Investor Conferences

  Read More
• 30 September 2021

  Jubilant Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for its Novel Dual LSD1 and HDAC6 Inhibitor JB1-802

  Read More
• 16 August 2021

  Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. and Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMO

  Read More
• 10 April 2021

  Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021

  Read More
• 08 March 2021

  Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

  Read More
• 25 February 2021

  Jubilant Therapeutics Announces Research Collaboration with Boston Children’s Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

  Read More
• 05 February 2021

  Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors

  Read More
• 15 January 2021

  Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

  Read More
• 07 December 2020

  Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers

  Read More
• 24 November 2020

  Jubilant Therapeutics Announces Upcoming Presentation at 2020 ASH Virtual Annual Meeting

  Read More
• 12 November 2020

  Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology

  Read More
• 04 November 2020

  Jubilant Therapeutics to Participate in Upcoming Investor Conferences

  Read More
• 20 October 2020

  Jubilant Therapeutics Strengthens Scientific Advisory Board

  Read More
• 22 June 2020

  Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research, Reveals Unique Dual-Action Anti-Cancer Mechanism Underscoring First-in-Class Pipeline Asset in Hematological Tumors

  Read More